Jay Olson
Stock Analyst at Oppenheimer
(3.56)
# 828
Out of 4,869 analysts
245
Total ratings
41.24%
Success rate
7.2%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Assumes: Outperform | $97 | $42.90 | +126.11% | 1 | Jun 2, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $5.72 | - | 14 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $25.73 | +152.62% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $5.15 | +1,162.14% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $1.96 | +563.27% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $39.66 | +89.11% | 9 | May 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $25 → $21 | $2.56 | +720.31% | 2 | May 7, 2025 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | $90 | $8.51 | +957.58% | 6 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $50 → $42 | $13.89 | +202.38% | 4 | Mar 3, 2025 | |
| EXEL Exelixis | Downgrades: Perform | $41 → $33 | $40.37 | -18.26% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $9.20 | +334.78% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.55 | +1,190.32% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $8.72 | +244.04% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $3.90 | +412.82% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $127.04 | +100.72% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $9 → $8 | $9.30 | -13.98% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $68.46 | +19.78% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $285.73 | +22.49% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $3.37 | +196.74% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $26.01 | +430.57% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.77 | +351.98% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $7.41 | +547.77% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $289.33 | +31.34% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $126.55 | +73.05% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.22 | +440.54% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $2.97 | +506.06% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.80 | +1,143.16% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $44.25 | +114.69% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $22.71 | -16.34% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.16 | +1,057.41% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $37.41 | +100.48% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.26 | +3,429.41% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $10.08 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $1.03 | +4,754.37% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $7.18 | +192.48% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.68 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $19.17 | +338.18% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.09 | - | 3 | Jul 11, 2017 |
Praxis Precision Medicines
Jun 2, 2025
Assumes: Outperform
Price Target: $97
Current: $42.90
Upside: +126.11%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $5.72
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $25.73
Upside: +152.62%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $5.15
Upside: +1,162.14%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.96
Upside: +563.27%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $39.66
Upside: +89.11%
Immuneering
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $2.56
Upside: +720.31%
Nektar Therapeutics
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $8.51
Upside: +957.58%
Denali Therapeutics
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $13.89
Upside: +202.38%
Exelixis
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $40.37
Upside: -18.26%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $9.20
Upside: +334.78%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.55
Upside: +1,190.32%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $8.72
Upside: +244.04%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $3.90
Upside: +412.82%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $127.04
Upside: +100.72%
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $9.30
Upside: -13.98%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $68.46
Upside: +19.78%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $285.73
Upside: +22.49%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $3.37
Upside: +196.74%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $26.01
Upside: +430.57%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.77
Upside: +351.98%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $7.41
Upside: +547.77%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $289.33
Upside: +31.34%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $126.55
Upside: +73.05%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.22
Upside: +440.54%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $2.97
Upside: +506.06%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.80
Upside: +1,143.16%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $44.25
Upside: +114.69%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $22.71
Upside: -16.34%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $2.16
Upside: +1,057.41%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $37.41
Upside: +100.48%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.26
Upside: +3,429.41%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $10.08
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $1.03
Upside: +4,754.37%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $7.18
Upside: +192.48%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.68
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $19.17
Upside: +338.18%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.09
Upside: -